Verzenio Presents Potential Profit After Prior Remedy in HR+/HER2– Breast Most cancers

Information from the retrospective rAMBER examine, introduced on the 2025 San Antonio Breast Most cancers Symposium(SABCS), confirmed that Verzenio (abemaciclib) monotherapy supplied scientific profit to some sufferers with hormone receptor (HR)–optimistic, HER2-negative breast most cancers who had progressed on prior CDK4/6 inhibitor remedy.

The examine evaluated how efficient Verzenio could possibly be when used alone after development on earlier CDK4/6 remedy, providing perception into the potential of sequential remedy on this affected person inhabitants.

Roughly 33% of sufferers who acquired Verzenio throughout 4 tutorial facilities (30 sufferers) derived significant scientific profit from the remedy. Verzenio was typically properly tolerated for greater than 180 days, even in sufferers whose illness had progressed on prior Ibrance remedy and ongoing endocrine therapies. Most sufferers (23 of 30) continued on Verzenio till both illness development or demise, whereas the remaining 7 sufferers discontinued remedy resulting from unintended effects.

The median period of remedy with Verzenio was 4 months following development on Ibrance-based remedy, and the median variety of intervening strains of remedy between Ibrance and Verzenio was 2, highlighting the potential of Verzenio to supply illness management even after a number of prior therapies.

“CDK4/6 inhibitors have grow to be the usual of look after sufferers with superior HR-positive, HER2-negative breast most cancers. Nonetheless, uncertainty stays concerning the efficacy of re-introducing CDK4/6 inhibitors after illness development on prior remedy,” mentioned Dr. Sahar Shahamatdar, an inner medication resident at Massachusetts Normal Hospital, and her coauthors. “rAMBER is the primary examine to judge the effectiveness of Verzenio monotherapy on this setting, providing new insights into sequential CDK4/6 remedy and potential remedy methods for sufferers who’ve exhausted normal choices.”

Verzenio was authorised by the U.S. Meals and Drug Administration (FDA) in February 2018 to be used together with an aromatase inhibitor as a frontline remedy for postmenopausal girls with HR-positive, HER2-negative superior or metastatic breast most cancers. This determination was supported by prior part 3 MONARCH 3 knowledge exhibiting a median progression-free survival of 28.2 months with Verzenio versus 14.8 months for sufferers receiving placebo, confirming its efficacy in first-line settings.

The rAMBER examine collected retrospective affected person knowledge from Massachusetts Normal Hospital, Barnes-Jewish Hospital, College of Pittsburgh Medical Heart, and Moffitt Most cancers Heart. Sufferers with metastatic HR-positive, HER2-negative breast most cancers who acquired Verzenio monotherapy after illness development on a CDK4/6 inhibitor–based mostly routine have been included. Sufferers have been divided into two subgroups: sequential CDK4/6 remedy (6 sufferers) and nonsequential remedy (24 sufferers). Information have been collected beneath Institutional Evaluate Board–authorised protocols, analyzing affected person demographics, scientific outcomes, and remedy period. Serial RECIST measurements have been collected from imaging research, and stable tumor and cell-free DNA have been analyzed utilizing focused sequencing.

Every biopsy was assigned a phenotype based mostly on the very best scientific response and period of response relative to biopsy timing, outlined as delicate, acquired resistant, or intrinsically resistant. One affected person achieved a partial response with Verzenio, seven sufferers skilled secure illness, and eight skilled illness development. Genomic evaluation of 23 biopsies confirmed RB1 alterations have been related to acquired or intrinsic resistance, and ESR1 alterations have been discovered throughout all biopsy phenotypes.

“Preliminary genetic analyses revealed enrichment in RB1 alterations in sufferers with fast illness development,” Shahamatdar and her coauthors concluded. These findings spotlight the potential of Verzenio monotherapy to offer scientific profit even after prior CDK4/6 inhibitor remedy and exhibit the significance of understanding tumor genetics when contemplating sequential remedy methods for superior breast most cancers.

References

1. “Up to date analyses from the retrospective rAMBER examine exploring abemaciclib after prior CDK4/6 inhibitor development in metastatic hormone-receptor optimistic breast most cancers,” by Dr. Sahar Shahamatdar, et al. Introduced at: San Antonio Breast Most cancers Symposium; December 9-12, 2025; San Antonio, TX. Summary PS1-10-01.
2. “FDA approves abemaciclib as preliminary remedy for HR-positive, HER2-negative metastatic breast most cancers,” by the U.S. FDA. Information launch; Feb. 26, 2018.

For extra information on most cancers updates, analysis and training, don’t overlook to subscribe to CURE®’s newsletters right here.